Lestaurtinib

From WikiMD's Food, Medicine & Wellness Encyclopedia

Lestaurtinib

Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor structurally related to staurosporine, and is being developed by Cephalon.

It is an inhibitor of FLT3,[1] JAK2,[2] TrkA, TrkB and TrkC.[3]

Uses[edit | edit source]

It is undergoing research for the treatment of acute myelogenous leukemia (AML) and myeloproliferative disorders.

As of 2009


, it is in Phase II clinical trials for AML and Phase II clinical trials for myeloproliferative disorders.[4][5]

See also[edit | edit source]

References[edit | edit source]

  1. ↑
  2. ↑
  3. ↑
  4. ↑ "Oncology pipeline Oct 2009" (PDF).
  5. ↑ "Trials of Lestaurinib".

Stub icon

This pharmacology-related article is a stub. You can help WikiMD by expanding it.

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Retrieved from "https://wikimd.com/w/index.php?title=Lestaurtinib&oldid=4970072"

Contributors: Prab R. Tumpati, MD